Scientific article
English

Comparison of outcomes of BuCy versus BuCyMel as preparation for allogeneic HSCT in infants with acute myeloid leukemia in first complete remission : a multicenter study from the EBMT PDWP

Published in

Bone marrow transplantation, vol. 61, no. 1, p. 67-74

Publication date

2026-01

First online date

2025-10-28

Abstract

Allogeneic haematopoietic stem cell transplantation (HSCT) is an essential treatment component for high-risk paediatric acute myeloid leukaemia (AML), but the choice of the optimal conditioning regimen remains controversial. We compared outcomes of two widely used myeloablative regimens, BuCy (Busulfan, Cyclophosphamide) versus BuCyMel (Busulfan, Cyclophosphamide, Melphalan) in children aged under 2 years undergoing HSCT in 1st complete remission (CR1). This international, registry-based study was conducted by the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplant (EBMT) and included patients transplanted from 2000-2022. 335 patients, transplanted across 98 centres, were included, 185 (55.2%) patients received BuCy and 150 patients (44.8%) received BuCyMel. BuCyMel was associated with significantly better leukaemia-free survival (LFS) (4 y: 74.8% vs 58.8%, HR 0.52 (95%CI: 0.33-0.82), p = 0.004) and overall survival (OS) (4 y: 77.9% vs 66.2%, HR 0.55 (95%CI: 0.33-0.91), p = 0.02) compared with BuCy, and significantly lower relapse incidence (4 y: 18.1% BuCyMel vs 31.5% BuCy, HR 0.50 (95%CI 0.29-0.87), p = 0.01). Four-year non-relapse mortality (NRM) did not differ between groups. Our results suggest that BuCyMel is a better conditioning regimen compared with BuCy in children aged under 2 years undergoing HSCT for CR1 AML.

Keywords

  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Male
  • Allografts
  • Busulfan / pharmacology
  • Busulfan / therapeutic use
  • Busulfan / administration & dosage
  • Cyclophosphamide / pharmacology
  • Cyclophosphamide / therapeutic use
  • Disease-Free Survival
  • Hematopoietic Stem Cell Transplantation / methods
  • Leukemia, Myeloid, Acute / therapy
  • Leukemia, Myeloid, Acute / mortality
  • Melphalan / pharmacology
  • Melphalan / therapeutic use
  • Melphalan / administration & dosage
  • Remission Induction
  • Transplantation Conditioning / methods
  • Transplantation, Homologous / methods
  • Treatment Outcome

Citation (ISO format)

WILLASCH, Andre Manfred et al. Comparison of outcomes of BuCy versus BuCyMel as preparation for allogeneic HSCT in infants with acute myeloid leukemia in first complete remission : a multicenter study from the EBMT PDWP. In: Bone marrow transplantation, 2026, vol. 61, n° 1, p. 67–74. doi: 10.1038/s41409-025-02734-8

Main files (1)

Article (Published version)

Identifiers

Additional URL for this publication

https://www.nature.com/articles/s41409-025-02734-8

Journal ISSN

0268-3369
8views
0downloads

Technical informations

Creation

02/10/2026 10:26:49

First validation

13/10/2026 07:25:00

Update

13/10/2026 07:25:00

Status update

13/10/2026 07:25:00

Last indexation

29/10/2026 12:22:50
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated